Journal
DRUGS & AGING
Volume 40, Issue 1, Pages 33-48Publisher
ADIS INT LTD
DOI: 10.1007/s40266-022-00989-0
Keywords
-
Categories
Ask authors/readers for more resources
The role of nicotinamide adenine dinucleotide (NAD+) in aging and its links to chronic diseases are discussed in this review. The mechanisms behind age-associated NAD+ decline are not well understood, but supplements aimed at increasing NAD+ levels are becoming popular. The clinical utility and benefits of NAD+ precursors in attenuating NAD+ decline and age-related disorders are explored.
The role of nicotinamide adenine dinucleotide (NAD+) in ageing has emerged as a critical factor in understanding links to a wide range of chronic diseases. Depletion of NAD+, a central redox cofactor and substrate of numerous metabolic enzymes, has been detected in many major age-related diseases. However, the mechanisms behind age-associated NAD+ decline remains poorly understood. Despite limited conclusive evidence, supplements aimed at increasing NAD+ levels are becoming increasingly popular. This review provides renewed insights regarding the clinical utility and benefits of NAD+ precursors, namely nicotinamide (NAM), nicotinic acid (NA), nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), in attenuating NAD+ decline and phenotypic characterization of age-related disorders, including metabolic, cardiovascular and neurodegenerative diseases. While it is anticipated that NAD+ precursors can play beneficial protective roles in several conditions, they vary in their ability to promote NAD+ anabolism with differing adverse effects. Careful evaluation of the role of NAD(+), whether friend or foe in ageing, should be considered.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available